Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World StudyD.J. Hughes, Alexandros Georgiou, Matthaios Kapiris et al.|Cancers|2022Cited by 22
[99mTc]-labelled anti-Programmed Death-Ligand 1 single-domain antibody SPECT/CT: a novel imaging biomarker for myocardial PD-L1 expressionMuhummad Sohaib Nazir, Vicky Goh, D.J. Hughes et al.|EJNMMI Research|2023Cited by 9
A Retrospective Evaluation of PD-L1 Expression and Heterogeneity in Early-Stage Non-Small Cell Lung Cancer (REPLICA)Eleni Josephides, Eleni Karapanagiotou, Daniel Smith et al.|Clinical Lung Cancer|2025Cited by 5
PD-L1 imaging with [99mTc]NM-01 SPECT/CT is associated with metabolic response to pembrolizumab with/without chemotherapy in advanced lung cancerD.J. Hughes, Gary Cook, Gitasha Chand et al.|British Journal of Cancer|2025Cited by 4
Association of baseline characteristics and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (CPIs): Real-world evidence.Danielle Crawley, Sharmistha Ghosh, Kerri Beckmann et al.|Journal of Clinical Oncology|2020Cited by 1